Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{181547,
        author = {Anjali G and Radhika. Ch and YVL. Keerthi Reddy and Anjali. P},
        title = {RESEALED ERYTHROCYTES: A NOVEL APPROACH IN TARGETED CANCER THERAPY},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {1},
        pages = {6084-6093},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=181547},
        abstract = {To explore the various features, drug loading technology, biomedical application of resealed erythrocytes. Resealed Erythrocyte has the ability to move throughout the body, biocompatibility, zero order kinetics of drugs, reproducibility and ease of preparation. Resealed erythrocytes, are an innovative platform in treating cancer, allow for precise drug delivery with very limited systemic toxicity. Engineered RBCs are prepared by making temporary pores in the cell membrane under hypotonic conditions, followed by loading therapeutic agents such as chemotherapeutics (L-asparaginase, sorafenib), genetic materials, or nanoparticles, and finally resealing the cells to retain their membrane integrity. With their biocompatibility, biodegradability, and long-circulating time, resealed erythrocytes have huge potential to overcome all the problems associated with traditional cancer therapy. More recent work has been towards surface modification techniques, which involve conjugation with tumour-specific ligands, monoclonal antibodies, or peptides, enabling cancerous tissues to be targeted with specificity. Magnetic guidance systems incorporate nanoparticles within erythrocytes for external control, using magnetic fields to direct the drug-loaded cells to target tumour sites. In addition, bio responsive systems release their therapeutic payloads in response to various stimuli, such as pH or enzymes, present in the tumour microenvironment, to facilitate drug action. Integration of resealed erythrocytes with some of the more advanced technologies, such as AI. While challenges in scalability, regulatory approval, and storage stability remain, resealed erythrocytes hold transformative potential in cancer therapy, ushering in a new epoch in precision medicine that promises not only safer but also more effective solutions in the fight against cancer.},
        keywords = {resealed erythrocytes, targeted cancer therapy, drug delivery, tumour-specific targeting, precision medicine.},
        month = {July},
        }